No Data
No Data
Why Investors Shouldn't Be Surprised By Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 39% Share Price Surge
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): Received the Notice of Acceptance of Clinical Trial Application for house dust mite film agent.
Gelonghui September 26th | Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that Zhejiang Wolwo Bio-Pharmaceutical Technology Co., Ltd. has received the "Acceptance Letter" issued by the National Medical Products Administration for the drug clinical trial application of "House Dust Mite Membrane Agent" (referred to as "this product"). The company's leading product "Dust Mite Drop Agent" (National Drug Approval No. S20060012, commodity name: Changdi) is clinically used for desensitization therapy of allergic rhinitis and allergic asthma caused by dust mite allergies, administered sublingually, in liquid drop form. The clinical trial this time
Zhejiang Wolwo Bio-pharmaceutical (300357.SZ) joint venture company developed a clinical trial summary report for "Inhalable Aescin A Solution"
Zhejiang Wolwo Bio-pharmaceutical (300357.SZ) released an announcement that its joint venture company, Shanghai Kaiyi Pharmaceutical Technology Co., Ltd. (referred to as...
Are Investors Undervaluing Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) By 49%?
Zhejiang Wolwo Bio-Pharmaceutical: Summary of Half-Year Report in 2024.
Zhejiang Wolwo Bio-Pharmaceutical: Half-year report for the year 2024.
No Data
No Data